Premium listings
  • DrugAge database of compounds that increase lifespan

    DrugAge database of compounds that increase lifespan

    Biomedical Sciences Liverpool August 24, 2015 Check with publisher

    We're starting a new database of drugs and compounds (including natural products) with anti-ageing properties that extend longevity in model organisms. The database will be called DrugAge, and although we have some data already, we are looking for da...

Listings
  • Anti-CEACAM5 (clone huMAb2-2)-SPDB-DM4 ADC

    Anti-CEACAM5 (clone huMAb2-2)-SPDB-DM4 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CEACAM5 monoclonal antibody (clone huMAb2-2) conjugated via a SPDB linker to a DM4. The DM4 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis...

  • Anti-CEACAM5 (clone chMAb1)-SPDB-DM4 ADC

    Anti-CEACAM5 (clone chMAb1)-SPDB-DM4 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CEACAM5 monoclonal antibody (clone chMAb1) conjugated via a SPDB linker to a DM4. The DM4 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. ...

  • Anti-CEACAM5 (clone chMAb5)-SPDB-DM4 ADC

    Anti-CEACAM5 (clone chMAb5)-SPDB-DM4 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CEACAM5 monoclonal antibody (clone chMAb5) conjugated via a SPDB linker to a DM4. The DM4 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. ...

  • Anti-CEACAM5 (clone chMAb4)-SPDB-DM4 ADC

    Anti-CEACAM5 (clone chMAb4)-SPDB-DM4 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CEACAM5 monoclonal antibody (clone chMAb4) conjugated via a SPDB linker to a DM4. The DM4 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. ...

  • Anti-CEACAM5 (clone chMAb2)-SPDB-DM4 ADC

    Anti-CEACAM5 (clone chMAb2)-SPDB-DM4 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CEACAM5 monoclonal antibody (clone chMAb2) conjugated via a SPDB linker to a DM4. The DM4 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. ...

  • Anti-CD79b (SN8)-SPP-DM1 ADC

    Anti-CD79b (SN8)-SPP-DM1 ADC

    Drug Development Shirley (New York) November 22, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CD79B monoclonal antibody (SN8) conjugated via a SPP linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cel...

  • Anti-CD74 (clone hLL1)-SMCC-Dox ADC

    Anti-CD74 (clone hLL1)-SMCC-Dox ADC

    Drug Development New York (New York) November 16, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CD74 monoclonal antibody (clone hLL1) conjugated via a SMCC linker to DOX. The DOX is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within ...

  • Anti-CD74 (clone hLL1)-SMCC-Dox ADC

    Anti-CD74 (clone hLL1)-SMCC-Dox ADC

    Drug Development New York (New York) November 16, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CD74 monoclonal antibody (clone hLL1) conjugated via a SMCC linker to DOX. The DOX is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within ...

  • Anti-CD72 (10D6.8.1)-SPP-DM1 ADC

    Anti-CD72 (10D6.8.1)-SPP-DM1 ADC

    Drug Development New York (New York) November 16, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CD72 monoclonal antibody (10D6.8.1) conjugated via a SPP linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the...

  • Anti-CD72 (10D6.8.1)-SPP-DM1 ADC

    Anti-CD72 (10D6.8.1)-SPP-DM1 ADC

    Drug Development New York (New York) November 15, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CD72 monoclonal antibody (10D6.8.1) conjugated via a SPP linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the...

  • What is Project Management in Pharmaceutical Industry Seminar

    What is Project Management in Pharmaceutical Industry Seminar

    Training and Teaching San Diego, CA (San Diego, CA) November 9, 2017 1295.00 Dollar US$

    Course "Risk Based Project Management for the Life Sciences Industry" has been pre-approved by RAPS as eligible for up to 12 credits towards a participant's RAC recertification upon full completion. Overview: Project management is a discipline that c...

  • Differences between Device and Drug Clinical Research - A Jeopardy Learning Game

    Differences between Device and Drug Clinical Research - A Jeopardy Learning Game

    Medical - Health Fremont (California) October 9, 2017 Check with publisher

    Training Options Duration: 60 Minutes Tuesday, November 28, 2017 | 10:00 AM PDT | 01:00 PM EDT Overview: Drug and device research is confusing and difficult on its own but when you start combining drugs with devices the regulatory landscape changes a...